The Latest Cardiac and Vascular News
Use of coronary CTA instead of stress tests alone results in increased early initiation of preventative therapy and 41% reduction in cardiac death and myocardial infarction1 Publication in the Journal of the American College of Cardiology advocates coronary CTA to detect atherosclerosis and coronary artery blockages versus invasive imaging or […]
Nine-month results from FORECAST trial show statistically significant reduction in unnecessary invasive cardiac testing, increase in catheterization lab efficiency, and reduction in repeat non-invasive testing REDWOOD CITY, Calif.–(BUSINESS WIRE)–Late-breaking results presented today confirm that incorporating the HeartFlow® FFRct Analysis into a coronary computed tomography angiogram (CTA)-led diagnostic pathway significantly increases overall […]
REDWOOD CITY, Calif.–(BUSINESS WIRE)–HeartFlow, Inc. today announced that it has obtained clearance from the U.S. Food and Drug Administration (FDA) for the HeartFlow Planner, a non-invasive, real-time virtual modeling tool for coronary artery disease (CAD) intervention. The HeartFlow Planner will enable interventional cardiologists to virtually model clinical scenarios vessel-by-vessel, explore treatment strategies […]
REDWOOD CITY, Calif.–(BUSINESS WIRE)–HeartFlow, Inc. today announced that NHS England has extended HeartFlow’s participation in the Innovation and Technology Payment (ITP) program for an additional year. As part of the extension, NHS England will provide reimbursement to NHS hospitals for the usage of the HeartFlow FFRct Analysis, a non-invasive cardiac test for stable […]
REDWOOD CITY, Calif.–(BUSINESS WIRE)–HeartFlow, Inc. today announced that it has named Dana G. Mead, Jr. as President and Chief Executive Officer (CEO). Mead also has been appointed to HeartFlow’s Board of Directors. Former President and CEO John H. Stevens, M.D., will continue to serve on the Board of Directors and […]
REDWOOD CITY, Calif.–(BUSINESS WIRE)–HeartFlow, Inc., today announced new data demonstrating that the use of the investigational HeartFlow Planner, a real-time, non-invasive interactive planning tool, led to a change in treatment strategy in 45% of patients with coronary artery disease (CAD) and reduced the need for invasive physiology. The data from […]
REDWOOD CITY, Calif.–(BUSINESS WIRE)–HeartFlow, Inc. today announced the findings of a new consumer survey of more than 1,500 adults across the United States that sheds light on dangerous misconceptions and lack of awareness around heart disease, the leading killer in the U.S. The research shows that while most people are optimistic […]
REDWOOD CITY, Calif.–(BUSINESS WIRE)–HeartFlow, Inc. today announced the start of the Prospective Randomized Trial of the Optimal Evaluation of Cardiac Symptoms and Revascularization (PRECISE) trial. The first patient was enrolled by Michael C. Turner, M.D., at Imperial Health Cardiovascular Specialists in Lake Charles, LA. The PRECISE trial is designed to compare the usual approach of diagnosing […]
REDWOOD CITY, Calif.–(BUSINESS WIRE)–HeartFlow, Inc. today announced that the Japanese Ministry of Health, Labor and Welfare (MHLW) has approved the recommendation by the Central Social Insurance Medical Council (Chuikyo) to provide reimbursement for the HeartFlow FFRct Analysis. The HeartFlow Analysis has already received regulatory approval from the Japanese Pharmaceuticals and Medical […]
MUNICH–(BUSINESS WIRE)–Late-breaking data published and presented today confirm that the non-invasive HeartFlow®FFRct Analysis enables physicians to effectively differentiate patients in need of coronary stenting or bypass surgery from those who can be managed with medications alone. The ADVANCE Registry was published in the European Heart Journal (EHJ) and the Aarhus University Hospital […]
